{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:13:26Z","timestamp":1792782806803,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum W\u00fcrzburg","id":[{"id":"https:\/\/ror.org\/03pvr2g57","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oral Maxillofac Surg"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>PD-L1 expression is an established predictive biomarker for immune checkpoint inhibitor therapy in recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), including oral squamous cell carcinoma (OSCC). However, the spatial heterogeneity of PD-L1 and additional biomarkers such as c-MET between primary tumors and lymph node metastases remains insufficiently characterized. Given the potential for compartment-specific biomarker differences between primary tumors and metastatic lesions, we investigated PD-L1 and c-MET expression patterns in matched primary tumors and lymph node metastases of OSCC patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this retrospective cohort study, PD-L1 expression (Tumor Proportion Score [TPS], Combined Positive Score [CPS]) and c-MET expression (H-score, percentage-based scoring) were analyzed by immunohistochemistry in primary tumors from 59 OSCC patients. Matched primary tumor\u2013lymph node metastasis pairs were available for 24 patients and served as the basis for the paired spatial heterogeneity analyses. Biomarker concordance between primary tumors and metastases as well as associations with clinicopathologic parameters were evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Both PD-L1 and c-MET were frequently expressed in primary tumors but showed significantly lower expression levels in matched lymph node metastases. Higher PD-L1 expression in primary tumors was associated with nodal metastasis in exploratory analyses, whereas c-MET expression showed no significant association with nodal status. No significant correlation between PD-L1 and c-MET expression was observed. Furthermore, discordance of PD-L1 CPS status between primary tumors and lymph node metastases resulted in different biomarker classifications in a substantial subset of matched cases. In exploratory analyses, biomarker expression and primary tumor\u2013lymph node discordance were not significantly associated with recurrence, although the limited number of events precludes definitive conclusions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our findings demonstrate pronounced spatial heterogeneity of PD-L1 and c-MET expression in OSCC and reveal compartment-specific biomarker expression patterns between primary tumors and lymph node metastases. The observed discordance between tumor compartments warrants further investigation in larger prospective studies to determine its biological and potential clinical relevance for biomarker assessment in OSCC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10006-026-01638-1","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T06:10:08Z","timestamp":1789539008000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Exploring spatial heterogeneity of PD-L1 and c-MET expression in oral squamous cell carcinoma"],"prefix":"10.1007","volume":"30","author":[{"given":"Cornelius","family":"Busse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1204-0368","authenticated-orcid":false,"given":"Marius","family":"H\u00f6rner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babak","family":"Saravi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Haug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Gubik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"K\u00fcbler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urs","family":"M\u00fcller-Richter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Rosenwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"key":"1638_CR1","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41572-020-00224-3","volume":"6","author":"DE JOHNSON","year":"2020","unstructured":"Johnson DE, Burtness B, Leemans, C. R., Lui, V. W. Y., Bauman, J. E., Grandis JR (2020) Head and neck squamous cell carcinoma. Nat Rev Dis Primers 6:92","journal-title":"Nat Rev Dis Primers"},{"key":"1638_CR2","first-page":"209","volume":"71","author":"H SUNG","year":"2021","unstructured":"Sung H, Siegel Ferlayj, Laversanne RL, Soerjomataram M, Jemal I, A., Bray F (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 71:209\u2013249","journal-title":"CA Cancer J Clin"},{"key":"1638_CR3","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1056\/NEJMoa2415434","volume":"393","author":"R UPPALURI","year":"2025","unstructured":"Uppaluri R, Haddad RI, Tao Y, Le Tourneau C, Lee NY, Westra W, Chernock R, Tahara M, Harrington KJ, Klochikhin AL, Bra\u00f1a I, Vasconcelos, Alves G, Hughes BGM, Oliva M, Pinto Figueiredo Lima I, Ueda T, Rutkowski T, Schroeder U, Mauz PS, FUEREDER T, LABAN S, ORIDATE N, POPOVTZER A, MACH N, KOROBKO Y, Costa DA, Hooda-Nehra A, Rodriguez CP, Bell RB, Manschot C, Benjamin K, Gumuscu B, Adkins D (2025) Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer. N Engl J Med 393:37\u201350","journal-title":"N Engl J Med"},{"key":"1638_CR4","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","volume":"394","author":"B BURTNESS","year":"2019","unstructured":"Burtness B, Souli\u00e8res Harringtonkjgreilr, Tahara D, DE M, Castro G, Psyrri JR, Bast\u00e9 A, Neupane N, Mes\u00eda Pbratland\u00e5fuerederthughesbgm, Ngamphaiboon R, Ishak nrordorftwan, Gonz\u00e1lez wzhongrl, Mendoza R, JIN Royazhangygumuscubchengjd, F., RISCHIN D (2019) Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 394:1915\u20131928","journal-title":"Lancet"},{"key":"1638_CR5","doi-asserted-by":"publisher","first-page":"105368","DOI":"10.1016\/j.oraloncology.2021.105368","volume":"119","author":"A KARABAJAKIAN","year":"2021","unstructured":"Karabajakian A, Michon Bouaoudj, Kamal L, Crozes M, Zrounba C, Auclair-Perossier P, Tourneau Jgadotnattignonvle, Benzerdjeb C, Fayette N, J., Saintigny P (2021) Longitudinal assessment of PD-L1 expression and gene expression profiles in patients with head and neck cancer reveals temporal heterogeneity. Oral Oncol 119:105368","journal-title":"Oral Oncol"},{"key":"1638_CR6","doi-asserted-by":"publisher","first-page":"4005","DOI":"10.1158\/1078-0432.CCR-16-0951","volume":"22","author":"S HARTMANN","year":"2016","unstructured":"Hartmann S, Bhola NE, Grandis JR (2016) HGF\/Met Signaling in Head and Neck Cancer: Impact on the Tumor Microenvironment. Clin Cancer Res 22:4005\u20134013","journal-title":"Clin Cancer Res"},{"key":"1638_CR7","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.oraloncology.2017.09.009","volume":"74","author":"P SZTURZ","year":"2017","unstructured":"Szturz P, Bud\u00edkov\u00e1 M, Horov\u00e1 Vermorkenjb, G\u00e1l I, Raymond B, De Gramont E, A., Faivre S (2017) Prognostic value of c-MET in head and neck cancer: A systematic review and meta-analysis of aggregate data. Oral Oncol 74:68\u201376","journal-title":"Oral Oncol"},{"key":"1638_CR8","doi-asserted-by":"publisher","first-page":"8110","DOI":"10.1074\/jbc.M114.612689","volume":"290","author":"M BALAN","year":"2015","unstructured":"Balan M, Mier Y Teran E, Waaga-gasser AM, Gasser M, Freeman Choueiritk, G., Pal s (2015) Novel roles of c-Met in the survival of renal cancer cells through the regulation of HO-1 and PD-L1 expression. J Biol Chem 290:8110\u20138120","journal-title":"J Biol Chem"},{"key":"1638_CR9","doi-asserted-by":"crossref","unstructured":"Boschert V, Aljasem Teuschj, Schmucker A, Klenk P, Bittrich Nstrauba, Seher M, Linz A, M\u00fcller-richter C, U. D. A., Hartmann S (2020) HGF-Induced PD-L1 Expression in Head and Neck Cancer: Preclinical and Clinical Findings. Int J Mol Sci, 21(22):877021","DOI":"10.3390\/ijms21228770"},{"key":"1638_CR10","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1038\/s41379-020-0644-7","volume":"34","author":"EJ DE RUITER","year":"2021","unstructured":"DE Ruiter EJ, Mulder FJ, Koomen BM, Speel EJ, Van Den Hout M, DE Roest RH, Bloemena E, Devriese, L. A., Willems SM (2021) Comparison of three PD-L1 immunohistochemical assays in head and neck squamous cell carcinoma (HNSCC). Mod Pathol 34:1125\u20131132","journal-title":"Mod Pathol"},{"key":"1638_CR11","doi-asserted-by":"publisher","first-page":"5336","DOI":"10.1002\/cncr.25537","volume":"116","author":"LH SOBIN","year":"2010","unstructured":"Sobin LH, Compton CC (2010) TNM seventh edition: what\u2019s new, what\u2019s changed: communication from the International Union Against Cancer and the American Joint Committee on Cancer. Cancer 116:5336\u20135339","journal-title":"Cancer"},{"key":"1638_CR12","doi-asserted-by":"publisher","first-page":"1498391","DOI":"10.3389\/fimmu.2024.1498391","volume":"15","author":"P JABBARZADEH KABOLI","year":"2024","unstructured":"Jabbarzadeh Kaboli P, Roozitalab G, Farghadani R, Eskandarian Z, Zerrouqi A (2024) c-MET and the immunological landscape of cancer: novel therapeutic strategies for enhanced anti-tumor immunity. Front Immunol 15:1498391","journal-title":"Front Immunol"},{"key":"1638_CR13","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/s41419-019-1769-9","volume":"10","author":"E ALSAHAFI","year":"2019","unstructured":"Alsahafi E, Begg K, Amelio I, Raulf N, Lucarelli P, Sauter T, Tavassoli M (2019) Clinical update on head and neck cancer: molecular biology and ongoing challenges. Cell Death Dis 10:540","journal-title":"Cell Death Dis"},{"key":"1638_CR14","first-page":"69","volume":"1","author":"C FREUDLSPERGER","year":"2010","unstructured":"Freudlsperger C, Alexander D, Reinert, S., Hoffmann J (2010) Prognostic value of c-Met expression in oral squamous cell carcinoma. Exp Ther Med 1:69\u201372","journal-title":"Exp Ther Med"},{"key":"1638_CR15","doi-asserted-by":"publisher","first-page":"104722","DOI":"10.1016\/j.oraloncology.2020.104722","volume":"106","author":"D LENOUVEL","year":"2020","unstructured":"Lenouvel D, Gonz\u00e1lez-Moles M, Ruiz-\u00c1vila I, Gonzalez-Ruiz L, Gonzalez-Ruiz I, Ramos-Garc\u00eda P (2020) Prognostic and clinicopathological significance of PD-L1 overexpression in oral squamous cell carcinoma: A systematic review and comprehensive meta-analysis. Oral Oncol 106:104722","journal-title":"Oral Oncol"},{"key":"1638_CR16","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.oraloncology.2018.09.016","volume":"86","author":"WF YANG","year":"2018","unstructured":"Yang WF, Wong MCM, Thomson PJ, Li KY, Su YX (2018) The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis. Oral Oncol 86:81\u201390","journal-title":"Oral Oncol"},{"key":"1638_CR17","doi-asserted-by":"crossref","unstructured":"Saravi B, Schorn Singhdd, Schrader Llommenj, Wilkat F, Vollmer Mvollmera, H\u00f6rner Mhartmanns, Adhikari M, Roider K, K\u00fcbler Ewollbornj (2026) N. & Sproll, C. Inverse relationship between neoantigen clonality and T-cell activity reveals distinct immune phenotypes in HNSCC. J Transl Med, 24","DOI":"10.1186\/s12967-026-08371-z"},{"key":"1638_CR18","doi-asserted-by":"publisher","first-page":"113120","DOI":"10.18632\/oncotarget.21303","volume":"8","author":"JH KIM","year":"2017","unstructured":"Kim JH, Kim BJ, Kim HS (2017) Clinicopathological impacts of high c-Met expression in head and neck squamous cell carcinoma: a meta-analysis and review. Oncotarget 8:113120\u2013113128","journal-title":"Oncotarget"},{"key":"1638_CR19","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/s41698-024-00671-1","volume":"8","author":"HL WILLIAMS","year":"2024","unstructured":"Williams HL, Frei AL, Koessler T, Berger MD, Dawson H, Michielin, O., Zlobec I (2024) The current landscape of spatial biomarkers for prediction of response to immune checkpoint inhibition. NPJ Precis Oncol 8:178","journal-title":"NPJ Precis Oncol"},{"key":"1638_CR20","doi-asserted-by":"crossref","unstructured":"Deazevedo R, Steiner M, Liu Turnerbx, Newton A, Fleming Sschmidtj, R., Tolentino, A., Kaseb, A. O., Curran MA (2024) Type I MET inhibitors cooperate with PD-1 blockade to promote rejection of hepatocellular carcinoma. J Immunother Cancer 12(10):e00969012","DOI":"10.1136\/jitc-2024-009690"},{"key":"1638_CR21","doi-asserted-by":"publisher","first-page":"6008","DOI":"10.1200\/JCO.2026.44.16_suppl.6008","volume":"44","author":"B BURTNESS","year":"2026","unstructured":"Burtness B, JI Harringtonkj, Calderon D, Lim B, Yang S, LI M-H, Kadowaki S-H, Swiecicki S, Ince Pgeigerjl, Hahn W, Guo D, Adkins Y, Toyoizumi Dcurtinjc, Kim Kwademsyilmaze, P., Rosenberg AJ (2026) Amivantamab in HPV-unrelated recurrent\/metastatic head and neck squamous cell cancer after disease progression on immune checkpoint inhibitor and chemotherapy: Pivotal results from the phase 1b\/2 OrigAMI-4 study. J Clin Oncol 44:6008\u20136008","journal-title":"J Clin Oncol"},{"key":"1638_CR22","doi-asserted-by":"crossref","unstructured":"Camidge DR, Ignatius Ottersongaclarkjw, OU SH, Shapiro Weissjadess, Socinski GI, Murphy MA, Conte DA, U., Tang, Y., Wang, S. C., Wilner, K. D., Villaruz LC (2021) Crizotinib in Patients With MET-Amplified NSCLC. J Thorac Oncol, 16, 1017\u20131029","DOI":"10.1016\/j.jtho.2021.02.010"},{"key":"1638_CR23","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1056\/NEJMoa2403991","volume":"392","author":"JA CHAN","year":"2025","unstructured":"Chan JA, Geyer S, Zemla T, Knopp MV, Behr S, Pulsipher S, Ou FS, Dueck AC, Acoba J, Shergill A, Wolin EM, Halfdanarson TR, Konda B, Trikalinos NA, TAWFIK B, RAJ N, Shaheen S, Vijayvergia N, Dasari A, Strosberg JR, Kohn EC, Kulke MH, O\u2019REILLY EM, MEYERHARDT JA (2025) Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors. N Engl J Med 392:653\u2013665","journal-title":"N Engl J Med"},{"key":"1638_CR24","doi-asserted-by":"publisher","first-page":"3851","DOI":"10.1200\/JCO.22.01994","volume":"41","author":"JE BAUMAN","year":"2023","unstructured":"Bauman JE, Saba NF, Roe D, Bauman JR, Kaczmar J, Bhatia A, Muzaffar J, JULIAN R, Wang S, Bearelly S, Baker A, Steuer C, Giri A, Burtness B, Centuori S, Caulin C, Klein R, Saboda K, Obara S, Chung CH (2023) Randomized Phase II Trial of Ficlatuzumab With or Without Cetuximab in Pan-Refractory, Recurrent\/Metastatic Head and Neck Cancer. J Clin Oncol 41:3851\u20133862","journal-title":"J Clin Oncol"}],"container-title":["Oral and Maxillofacial Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10006-026-01638-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10006-026-01638-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10006-026-01638-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T06:10:13Z","timestamp":1789539013000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10006-026-01638-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1638"],"URL":"https:\/\/doi.org\/10.1007\/s10006-026-01638-1","relation":{},"ISSN":["1865-1569"],"issn-type":[{"value":"1865-1569","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]},"assertion":[{"value":"22 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"149"}}